Clinical Trial Update: Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma [Phase 3]

View source ↗

Summary

A Phase 3 trial in Chinese participants with inadequately controlled asthma evaluating the efficacy and safety of the fixed-dose inhaler FF/UMEC/VI has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2025-08-11